Cancer Genetics

The deal will join CGI's portfolio of cancer tests and lab services with NovellusDx's technologies for cancer treatment response prediction.

The company is continuing to work with a financial advisor to evaluate strategic options, with discussions about potential transactions ongoing.

The increase was drive by revenue growth in Cancer Genetics' discovery services unit, which included the impact of recently acquired CRO VivoPharm.

The firm is selling BioServe to Reprocell as part of Cancer Genetics' transformation and strategic plan to bring itself to profitability.

The test is designed to identify a tumor's tissue of origin by assessing 2,000 individual genes and covers 15 common tumor types.

The lawsuits allege the company made false and/or misleading statement and/or failed to disclose information that was pertinent to investors.

The firm is in the midst of evaluating its strategic options and has hired Raymond James to assist in the process, which could include the sale of the firm, it said.